Form 4: CalciMedica CEO Rachel Leheny Granted Stock Options

Rachel Leheny, CEO of CalciMedica, Inc., was granted employee stock options on March 28, 2024.

Summary

• Rachel Leheny, the CEO of CalciMedica, Inc. (CALC), received employee stock options.
• The transaction occurred on March 28, 2024.
• Leheny was granted options to purchase 115,000 shares of common stock at an exercise price of $4.16 per share.
• The options vest in equal monthly installments over a four-year period, starting from the grant date.
• The options expire on March 27, 2034.
• The filing indicates Leheny's direct ownership of these derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CEO can align her interests with those of the shareholders, incentivizing her to increase the company's value.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. This grant is typical for companies of CalciMedica's size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to attract and retain top talent.
• The vesting schedule of 1/48th monthly over four years is a common vesting structure.
• The number of shares granted and the exercise price would be benchmarked against similar companies based on market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO.
• Employees may see this as a sign of confidence in the company's future.

Key Dates